Did you actually see the NYAS presentation -- the very first data slide said the the DCVax-L PFS endpoint was worse than placebo (but not significantly). I'll believe them.
NWBO was the one that chose PFS as the primary endpoint and it failed. Dance around it all you want, it failed and NWBO reported it failed. Changing every part of the trial -- protocol, endpoints, SAP, comparator right before the end of the trial is never legitimate. ECA particular was flagrant violation of FDA guidance that requires that is is designed BEFORE the trial begins. FDA's not going to buy they application.
Market Data 
Markets 
AI
